PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021457 001	ALBUTEROL SULFATE;ALBUTEROL SULFATE HF	5695743	JUL 06, 2010	DP U491		
>ADD>			5766573	NOV 29, 2009	U356		
			5605674	FEB 25, 2014	DP		
			6352684	NOV 28, 2009	DP		
	021726 001	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 002	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 003	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021726 004	ALPRAZOLAM;NIRAVAM	6221392	APR 09, 2018	DP		
			6024981	APR 09, 2018	DP		
	021713 001	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
						I-437	SEP 29, 2007
						I-401	AUG 28, 2006
	021248 001	ARSENIC TRIOXIDE;TRISENOX	6855339	NOV 10, 2018	U617		
			6861076	NOV 10, 2018	U617		
>ADD>	021411 007	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
>ADD>			5658590*PED	JAN 11, 2015		PED	MAY 26, 2008
>ADD>	021411 008	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
>ADD>			5658590*PED	JAN 11, 2015		PED	MAY 26, 2008
>ADD>	021602 001	BORTEZOMIB;VELCADE				I-452	MAR 25, 2008
>ADD>	021664 001	BROMFENAC SODIUM;XIBROM				NP	MAR 24, 2008
	020838 001	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 002	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 003	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	020838 004	CANDESARTAN CILEXETIL;ATACAND				I-448	FEB 22, 2008
	021710 001	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
	021710 002	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
	021710 003	CARBAMAZEPINE;EQUETRO	5326570	JUL 23, 2011	DP U627		
			5912013	JUN 15, 2016	DP		
>ADD>	021197 001	CETRORELIX;CETROTIDE	6863891	FEB 19, 2013	U426		
>ADD>	021197 002	CETRORELIX;CETROTIDE	6863891	FEB 19, 2013	U426		
	021673 001	CLOFARABINE;CLOLAR	5661136	AUG 26, 2014	U626		
			5384310	MAY 23, 2009	DS DP		
			4918179	JUN 14, 2005	DS		
>ADD>	020222 001	COLESTIPOL HYDROCHLORIDE;COLESTID	5490987	FEB 13, 2013	DP		
	021572 001	DAPTOMYCIN;CUBICIN	6852689	SEP 24, 2019	U282		
	021572 002	DAPTOMYCIN;CUBICIN	6852689	SEP 24, 2019	U282		
>ADD>	021513 001	DARIFENACIN HYDROBROMIDE;ENABLEX	6106864	AUG 21, 2016	DP U630		
>ADD>			5096890	MAR 13, 2010	DS DP U631		
>ADD>	021513 002	DARIFENACIN HYDROBROMIDE;ENABLEX	6106864	AUG 21, 2016	DP U630		
>ADD>			5096890	MAR 13, 2010	DS DP U631		
>ADD>	021271 001	DESIRUDIN RECOMBINANT;IPRIVASK				NCE	APR 04, 2008
	021605 001	DESLORATADINE;CLARINEX D 24 HOUR				NCE	DEC 21, 2006
						PED	JUN 21, 2007
>ADD>						NC	MAR 03, 2008
	076068 001	DEXRAZOXANE HYDROCHLORIDE;DEXRAZOXANE				PC	AUG 27, 2005
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6720004	DEC 18, 2018	DP		
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6720004	DEC 18, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021269 001	DOXAZOSIN MESYLATE;CARDURA XL				NDF	FEB 22, 2008
>ADD>	021269 002	DOXAZOSIN MESYLATE;CARDURA XL	4837111	MAR 21, 2008	DP	NDF	FEB 22, 2008
>ADD>	021504 001	EPINEPHRINE;LIDOSITE TOPICAL SYS	6862473	SEP 30, 2013	DP		
	021437 001	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021437 002	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021437 003	EPLERENONE;INSPRA	4559332	APR 09, 2005	DS DP U537		
	021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
			5652233	FEB 02, 2013		PED	MAY 21, 2007
			5952323	MAY 15, 2017			
			5478820*PED	AUG 02, 2013			
			5652233*PED	AUG 02, 2013			
			5952323*PED	NOV 15, 2017			
	076323 001	ESMOLOL HYDROCHLORIDE;ESMOLOL HCL				PC	MAY 01, 2005
>ADD>	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2006	DS DP U373		
>ADD>			4738974*PED	OCT 19, 2006	U635		
>ADD>			6875872	MAY 27, 2014	DS U373		
>ADD>			6875872*PED	NOV 27, 2014			
>ADD>	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2006	DS DP U373		
>ADD>			4738974*PED	OCT 19, 2006	U635		
>ADD>			6875872	MAY 27, 2014	DS U373		
>ADD>			6875872*PED	NOV 27, 2014			
>ADD>	021443 001	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284	NP	DEC 20, 2007
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 002	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284	NP	DEC 20, 2007
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 003	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284		
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021443 004	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA	6855703	FEB 12, 2021	DS DP U284		
>ADD>			6660726	MAR 08, 2021	DS DP U196		
					U284		
>ADD>	021476 001	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
>ADD>	021476 002	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
>ADD>	021476 003	ESZOPICLONE;LUNESTA	6864257	AUG 30, 2012	U629		
			6444673	JAN 16, 2012	DS DP		
			6319926	JAN 16, 2012	U620		
	021712 001	FAMOTIDINE;FLUXID	6024981	APR 09, 2018	DP		
			6221392	APR 09, 2018	DP		
	021712 002	FAMOTIDINE;FLUXID	6024981	APR 09, 2018	DP		
			6221392	APR 09, 2018	DP		
	020747 001	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 002	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 003	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 004	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 005	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			
	020747 006	FENTANYL CITRATE;ACTIQ	5785989	MAY 01, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	019813 005	FENTANYL;DURAGESIC-12				NPP	MAY 20, 2006
						PED	NOV 20, 2006
	021758 001	FLUOCINONIDE;VANOS				NP	FEB 11, 2008
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	6536427	MAR 01, 2011	DP		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	6536427	MAR 01, 2011	DP		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	6536427	MAR 01, 2011	DP		
>ADD>	021152 001	FLUTICASONE PROPIONATE;CUTIVATE				NDF	MAR 31, 2008
>ADD>						PED	SEP 30, 2008
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	6358527	JUN 06, 2017	DP U322		
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
			5464826	NOV 07, 2012	U146	PED	NOV 19, 2007
			4808614*PED	NOV 15, 2010			
			5464826*PED	MAY 07, 2013			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U146	I-428	MAY 19, 2007
			4808614	MAY 15, 2010	DS	PED	NOV 19, 2007
			4808614*PED	NOV 15, 2010			
			5464826*PED	MAY 07, 2013			
	020239 003	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	DS DP U89	I-369	AUG 16, 2005
	020239 004	GRANISETRON HYDROCHLORIDE;KYTRIL				I-369	AUG 16, 2005
>ADD>	021455 002	IBANDRONATE SODIUM;BONIVA				D-96	MAR 24, 2008
>ADD>						NS	MAR 24, 2008
>ADD>						NCE	MAY 16, 2008
	021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021588 001	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
	021588 002	IMATINIB MESYLATE;GLEEVEC	5521184	JAN 04, 2015			
>ADD>	076104 001	ITRACONAZOLE;ITRACONAZOLE				PC	AUG 08, 2005
	020726 001	LETROZOLE;FEMARA				I-446	OCT 29, 2007
	021731 001	LEUPROLIDE ACETATE;ELIGARD	RE37950	OCT 03, 2008	DP U621		
			4938763	OCT 03, 2008	DP U621		
			5278201	JAN 11, 2011	DP		
			5324519	JUN 28, 2011	DP		
			5599552	FEB 04, 2014	DP U621		
			5739176	OCT 03, 2008	DP U621		
			6395293	SEP 28, 2013	DP		
			6565874	OCT 28, 2018	DP U621		
			6626870	MAR 27, 2020	DP		
			6773714	OCT 28, 2018	U621		
>ADD>	021730 001	LEVALBUTEROL TARTRATE;XOPENEX HFA				NP	MAR 11, 2008
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
			5688792*PED	MAY 18, 2015		I-431	JUN 23, 2007
			6514529*PED	SEP 15, 2021		PED	JAN 22, 2007
			6559305*PED	JUL 29, 2021		PED	OCT 18, 2005
						PED	DEC 23, 2007
						PED	JUN 19, 2006
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
			5688792*PED	MAY 18, 2015		I-431	JUN 23, 2007
			6514529*PED	SEP 15, 2021		PED	JAN 22, 2007
			6559305*PED	JUL 29, 2021		PED	OCT 18, 2005
						PED	DEC 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
						PED	JUN 19, 2006
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			5688792*PED	MAY 18, 2015		I-402	JUL 22, 2006
			6559305*PED	JUL 29, 2021		I-431	JUN 23, 2007
						PED	JUN 19, 2006
						PED	JAN 22, 2007
						PED	OCT 18, 2005
						PED	DEC 23, 2007
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	NCE	APR 18, 2005
			6559305	JAN 29, 2021	DS	NPP	DEC 19, 2005
			5688792*PED	MAY 18, 2015		I-402	JUL 22, 2006
			6559305*PED	JUL 29, 2021		I-431	JUN 23, 2007
						PED	OCT 18, 2005
						PED	JAN 22, 2007
						PED	DEC 23, 2007
						PED	JUN 19, 2006
>ADD>	021316 001	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 002	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 003	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021316 004	LOVASTATIN;ALTOPREV	6485748	DEC 12, 2017	DP		
>ADD>	021583 001	MEDROXYPROGESTERONE ACETATE;DEPO-SUBQ PROVERA 10	6495534	MAY 15, 2020	DP	I-451	MAR 25, 2008
>ADD>	020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
>ADD>						I-430	JUL 16, 2007
>ADD>						PED	OCT 13, 2005
>ADD>						PED	JAN 16, 2008
>ADD>	021530 001	MELOXICAM;MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007
>ADD>			6184220*PED	SEP 25, 2019		NCE	APR 13, 2005
>ADD>						PED	OCT 13, 2005
>ADD>						PED	JAN 16, 2008
>ADD>	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET	6866866	MAR 17, 2021	DP		
>ADD>	021574 002	METFORMIN HYDROCHLORIDE;FORTAMET	6866866	MAR 17, 2021	DP		
	076863 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	APR 12, 2005
>ADD>	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	SEP 18, 2007	DP	D-95	FEB 15, 2008
>ADD>			4957745	SEP 18, 2007	DP U107		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	SEP 18, 2007	DP	D-95	FEB 15, 2008
>ADD>			4957745	SEP 18, 2007	DP U107		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	DP U107	D-95	FEB 15, 2008
>ADD>			5001161	SEP 18, 2007	DP		
>ADD>			5081154	SEP 18, 2007	DS		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	DP U107	D-95	FEB 15, 2008
>ADD>			5081154	SEP 18, 2007	DS U107		
>ADD>			4927640	MAY 22, 2007	DP		
>ADD>			5001161	SEP 18, 2007	DP U107		
>ADD>	021506 002	MICAFUNGIN SODIUM;MYCAMINE				NCE	MAR 16, 2010
>ADD>	020717 001	MODAFINIL;PROVIGIL				I-449	JAN 23, 2007
>ADD>	020717 002	MODAFINIL;PROVIGIL				I-449	JAN 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	DP U625		
			6127353	OCT 03, 2017	DS DP		
			6723713	JAN 27, 2014	U625		
>ADD>	021067 001	MOMETASONE FUROATE;ASMANEX TWISTHALER				NP	MAR 30, 2008
	021204 001	NATEGLINIDE;STARLIX	RE34878	SEP 08, 2009			
			6844008	NOV 14, 2017	DP U214		
	021204 002	NATEGLINIDE;STARLIX	RE34878	SEP 08, 2009			
			6844008	NOV 14, 2017	DP U214		
>ADD>	019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	021706 001	OMEPRAZOLE;ZEGERID	5840737	JUL 16, 2016	DS U623		
			6489346	JUL 16, 2016	DS DP U624		
			6645988	JUL 16, 2016	DS DP U623		
			6780882	JUL 16, 2016	DS DP U624		
			6699885	JUL 16, 2016			
					U623		
					U624		
>ADD>	020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				PED	SEP 25, 2008
>ADD>						D-97	MAR 25, 2008
>ADD>	020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE				PED	SEP 25, 2008
>ADD>						D-97	MAR 25, 2008
	021759 001	OXALIPLATIN;ELOXATIN				NCE	AUG 09, 2007
						I-441	NOV 04, 2007
	021759 002	OXALIPLATIN;ELOXATIN				NCE	AUG 09, 2007
						I-441	NOV 04, 2007
	021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
	021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
						PED	JUL 14, 2005
>ADD>	021660 001	PACLITAXEL;ABRAXANE	6749868	FEB 22, 2013	DP	NP	JAN 07, 2008
>ADD>			6537579	FEB 22, 2013	U632		
>ADD>			6753006	FEB 22, 2013	DP		
>ADD>			6506405	FEB 22, 2013	DP U633		
>ADD>			6096331	FEB 22, 2013	DP U633		
>ADD>			5498421	MAR 12, 2013	DP U634		
>ADD>			5439686	FEB 22, 2013	DP		
	021756 001	PEGAPTANIB SODIUM;MACUGEN	6051698	SEP 17, 2012	DS		
			5919455	OCT 27, 2013	DS		
			5932462	AUG 03, 2016	DS		
			6113906	OCT 27, 2013	DS		
			6011020	JAN 04, 2017	DS		
			6426335	JUN 11, 2010	U622		
			6147204	JUN 11, 2010	DS		
>ADD>	021332 001	PRAMLINTIDE ACETATE;SYMLIN				NCE	MAR 16, 2010
	021446 001	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 002	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021446 003	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 004	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 005	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 006	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 007	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021446 008	PREGABALIN;LYRICA	6001876	JUL 16, 2017	U55		
			6197819	MAR 06, 2018	DS DP		
	021511 001	RIBAVIRIN;COPEGUS				I-447	FEB 25, 2008
>ADD>	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	DS DP U329	I-453	FEB 28, 2008
>ADD>			5741803	APR 21, 2015	DS DP U628		
					U329		
					U628		
>ADD>	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5741803	APR 21, 2015	DS DP U329	I-453	FEB 28, 2008
>ADD>			5002953	AUG 30, 2008	DS DP U628		
					U329		
					U628		
>ADD>	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	DS DP U329	I-453	FEB 28, 2008
>ADD>			5741803	APR 21, 2015	DS DP U628		
					U329		
					U628		
>ADD>	021366 002	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 003	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 004	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
>ADD>	021366 005	ROSUVASTATIN CALCIUM;CRESTOR	6858618	DEC 17, 2021	U618		
	020645 001	SODIUM BENZOATE;AMMONUL				NDF	FEB 17, 2008
						ODE	FEB 17, 2012
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	NOV 20, 2018	DP		
>ADD>	021144 002	TELITHROMYCIN;KETEK				NCE	APR 01, 2009
>ADD>	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
>ADD>	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013	DS DP U619	ODE	MAR 15, 2012
>ADD>			5260291*PED	FEB 11, 2014		I-450	MAR 15, 2008
	020505 001	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 002	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 003	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 004	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 005	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007
	020505 006	TOPIRAMATE;TOPAMAX				I-41	AUG 11, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-41	AUG 11, 2007
>ADD>	021266 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021266 002	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021267 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
>ADD>	021630 001	VORICONAZOLE;VFEND	5567817	MAY 24, 2016	DS DP U540		
	021060 001	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 002	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 003	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		
	021060 004	ZICONOTIDE;PRIALT	5795864	JUN 27, 2015	DP		
			5364842	DEC 30, 2011	U48		
			5859186	DEC 30, 2011	U55		
					U48		
					U55		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.